Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
Shahid Nimjee, M.D., Ph.D.
Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University
Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial
About this Seminar
Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.
You May Also Be Interested In...
-
Home ItemBiobehavioral Susceptibility for Obesity: Behavioral, Genetic and Neuroimaging Studies of Appetite , home
Sept. 6, 2024, 11:00 a.m. | Susan Carnell, Ph.D., Associate Professor, Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine | Co-Sponsored by the Center for Health Behaviors Research and the Addiction Recovery Research Center, Fralin Biomedical Research Institute
-
Home ItemConducting the Neuro-Symphony in the Brain — Space, Time, and Calcium , home
Sept. 12, 2024, 5:30 p.m. (Reception at 5 p.m.) | Michael Friedlander, Ph.D., Executive Director, Fralin Biomedical Research Institute Vice President for Health Sciences and Technology, Virginia Tech Senior Dean for Research, Virginia Tech Carilion School of Medicine | Maury Strauss Distinguished Public Lecture
-
Home ItemDevelopment of Genome Editor Therapies for Angelman Syndrome , home
Sept. 13, 2024, 11:00 a.m. | Mark J. Zylka, Ph.D., W.R. Kenan, Jr. Distinguished Professor, University of North Carolina at Chapel Hill; Director, UNC Neuroscience Center | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute
-
Home ItemUnderstanding the Limits of Exercise Responsiveness in Older Adults , home
Sept. 20, 2024, 11:00 a.m. | Ian R. Lanza, Ph.D., Professor of Medicine, Mayo Clinic College of Medicine and Science | Co-Sponsored by the Center for Exercise Medicine Research, Fralin Biomedical Research Institute
-
Home ItemFrom Variant Functionality to Resistance in Cancer , home
Sept. 27, 2024, 11:00 a.m. | Tiki Hayes, Ph.D., Assistant Professor, Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – D.C.
-
Home ItemDisrupting Health Care Using Deep Data and Remote Monitoring , home
Oct. 4, 2024, 11:00 a.m. | Michael Snyder, Ph.D., Professor, Genetics, Director, Center for Genomics and Personalized Medicine, Stanford Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research